Case Report: Rare coexistence of primary Sjögren’s syndrome and IgA-type lymphoplasmacytic lymphoma successfully treated with rituximab and orelabrutinib

Background IgA-type lymphoplasmacytic lymphoma (LPL) is a rare type of non-Hodgkin lymphoma and is even rarer when combined with primary Sjögren’s syndrome (pSS). Currently, there is no unified early identification and standardized treatment plan. Methods and results This article reports a 67-year-old female patient with a history of pSS for more than 10 years. After she was admitted to the hospital with fever, multiple generalized lymph node enlargement and IgA-κ monoclonal immunoglobulinemia were found. After 18 months of treatment with glucocorticoids combined with traditional immunosuppressants (mycophenolate mofetil, cyclophosphamide, and iguratimod), lymph node enlargement persisted, and IgA levels fluctuated at a high level. Three consecutive bone marrow punctures and two lymph node biopsies revealed all benign lesions. A third lymph node resection biopsy and immunohistochemistry confirmed the diagnosis of IgA-type LPL. After six cycles of treatment with rituximab combined with orelabrutinib (RO regimen), the patient achieved complete remission. Subsequently, orelabrutinib monotherapy was continued as maintenance treatment. In October 2023, the patient remained stable, and orelabrutinib was discontinued. After that, the patient was followed up at the outpatient clinic. As of July 2026, the patient was in good condition with no signs of recurrence. Conclusion This case suggests that lymphoma should be considered in patients with pSS who have monoclonal immunoglobulins, refractory elevated erythrocyte sedimentation rate, persistent lymph node enlargement, and high disease activity despite treatment with various immunosuppressants. Lymph node biopsy should be repeated if necessary. For patients with pSS and suspected or confirmed lymphoma, B-cell-targeted therapy should be considered as early as possible. Rituximab combined with orelabrutinib was effective in this patient with IgA-type LPL.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-19
DOI
https://doi.org/10.3389/fimmu.2026.2015223
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Case Report: Rare coexistence of primary Sjögren’s syndrome and IgA-type lymphoplasmacytic lymphoma successfully treated with rituximab and orelabrutinib

Lei Zhang, 高招猛, Pengbo Xiao
Frontiers in Immunology
Lymphoma Diagnosis and Treatment
article

Case Report: Rare coexistence of primary Sjögren’s syndrome and IgA-type lymphoplasmacytic lymphoma successfully treated with rituximab and orelabrutinib

Lei Zhang, 高招猛, Pengbo Xiao
article en

Abstract

Background IgA-type lymphoplasmacytic lymphoma (LPL) is a rare type of non-Hodgkin lymphoma and is even rarer when combined with primary Sjögren’s syndrome (pSS). Currently, there is no unified early identification and standardized treatment plan. Methods and results This article reports a 67-year-old female patient with a history of pSS for more than 10 years. After she was admitted to the hospital with fever, multiple generalized lymph node enlargement and IgA-κ monoclonal immunoglobulinemia were found. After 18 months of treatment with glucocorticoids combined with traditional immunosuppressants (mycophenolate mofetil, cyclophosphamide, and iguratimod), lymph node enlargement persisted, and IgA levels fluctuated at a high level. Three consecutive bone marrow punctures and two lymph node biopsies revealed all benign lesions. A third lymph node resection biopsy and immunohistochemistry confirmed the diagnosis of IgA-type LPL. After six cycles of treatment with rituximab combined with orelabrutinib (RO regimen), the patient achieved complete remission. Subsequently, orelabrutinib monotherapy was continued as maintenance treatment. In October 2023, the patient remained stable, and orelabrutinib was discontinued. After that, the patient was followed up at the outpatient clinic. As of July 2026, the patient was in good condition with no signs of recurrence. Conclusion This case suggests that lymphoma should be considered in patients with pSS who have monoclonal immunoglobulins, refractory elevated erythrocyte sedimentation rate, persistent lymph node enlargement, and high disease activity despite treatment with various immunosuppressants. Lymph node biopsy should be repeated if necessary. For patients with pSS and suspected or confirmed lymphoma, B-cell-targeted therapy should be considered as early as possible. Rituximab combined with orelabrutinib was effective in this patient with IgA-type LPL.

Frontiers in ImmunologyVol. 17
Shengli Oilfield Central Hospital (CN)
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon